Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases

Table 4

PRRT therapeutic efficacy.

Modality	Best response	Frequency		PFS (mean ± SD (months))	PFS (median (months))
PRRT alone	CR	0/35	0%
	PR	12/35	34%	28.0 ± 28.2	17
	SD	19/35	54%
	PD	3/35	9%
	MR	1/35	3%
PRRT + SSA	CR	0/30	0%
	PR	16/30	53%	31.7 ± 18.1	27
	SD	14/30	47%
	PD	0/30	0%
	MR	0/30	0%